Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $118.33M
• Dividend Yield: N/A
• Average Volume (3M): 228.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: -3.98%
• EPS Growth: -29.94%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.82
• Shares Outstanding: 17,050,877
• 10 Day Avg. Volume: 494,784
• 30 Day Avg. Volume: 228,238
• PEG Ratio: 0.02
• Price to Book (P/B): -0.44
• Price to Sales (P/S): 0.57
• P/FCF Ratio: -0.65
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: 1.24
• Enterprise Value/Gross Profit: 1.29
• Enterprise Value/Ebitda: -2.19
• 1Y Price Target: $13.83
• Price Target Upside: 99.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $7.00 ▲(0.86% Upside)

Karyopharm Therapeutics' overall stock score is primarily impacted by its poor financial performance, which is a major concern. While there is some positive momentum in technical analysis and earnings call highlights, the negative valuation metrics and financial instability weigh heavily on the score.

Positive Factors

Revenue Growth

The 13.4% revenue growth indicates strong demand for Karyopharm's products, suggesting potential for sustained market expansion and financial improvement.

Clinical Progress

Advancing to Phase III trials positions Karyopharm to potentially introduce new therapies, enhancing its product pipeline and long-term growth prospects.

Financial Flexibility

Securing $100 million in financing strengthens Karyopharm's financial position, providing resources for strategic initiatives and reducing liquidity risk.

Negative Factors

Financial Instability

Negative equity highlights financial instability, posing risks to sustainability and limiting the company's ability to invest in growth opportunities.

Cash Flow Challenges

Persistent negative cash flow indicates operational inefficiencies and reliance on external financing, which could hinder long-term financial health.

Profitability Issues

Ongoing net losses reflect challenges in achieving profitability, impacting the company's ability to self-fund operations and invest in growth.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc. (KPTI) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of cancer and other serious diseases. The company specializes in the discovery and development of small molecule drugs that target the nuclear transport system, with a primary emphasis on its lead product, Xpovio (selinexor), which is designed to treat multiple myeloma and other malignancies. Karyopharm's innovative approach aims to address unmet medical needs in oncology, leveraging its proprietary SINE (Selective Inhibitor of Nuclear Export) technology platform.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the commercialization of its lead product, Xpovio, which has received approval from regulatory authorities for treating certain types of cancers. The company earns money through direct product sales to healthcare providers and patients. In addition, Karyopharm may also generate revenue from collaborations and partnerships with other pharmaceutical companies, which could include licensing agreements, research and development collaborations, and milestone payments. These partnerships often enable Karyopharm to share the costs and risks associated with drug development while providing additional financial resources that contribute to the company's overall earnings.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges, including declining revenues, persistent losses, high leverage, and negative equity. The company's cash flow is insufficient, leading to reliance on external financing.

Income Statement

Karyopharm Therapeutics has experienced declining revenue over recent years, with a negative revenue growth rate of -0.55% from 2023 to 2024. The company also faces significant profitability challenges, as indicated by negative net profit margins and EBIT margins. Despite a relatively high gross profit margin of 95.87% in 2024, the persistent net losses highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt relative to assets suggests significant leverage. The equity ratio is negative, further emphasizing the financial instability and potential solvency risks.

Cash Flow

Karyopharm Therapeutics has negative free cash flow, which deteriorated by 37.66% from 2023 to 2024. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Although there was a positive financing cash flow, it is insufficient to offset the negative operating cash flow, indicating reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	142.53M	145.24M	146.03M	157.07M	209.82M	108.08M
Gross Profit	136.73M	139.23M	141.09M	151.86M	206.42M	105.38M
EBITDA	-80.42M	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
Net Income	-124.62M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet
Total Assets	96.23M	164.42M	240.44M	358.17M	305.31M	313.05M
Cash, Cash Equivalents and Short-Term Investments	45.88M	108.71M	191.44M	277.97M	228.62M	249.24M
Total Debt	196.42M	194.52M	177.02M	179.07M	180.58M	131.13M
Total Liabilities	365.49M	350.44M	376.64M	374.83M	384.98M	262.50M
Stockholders Equity	-269.26M	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow
Free Cash Flow	-83.44M	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
Operating Cash Flow	-83.49M	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
Investing Cash Flow	48.37M	95.47M	7.94M	-104.26M	141.84M	-53.69M
Financing Cash Flow	1.04M	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Positive. The current price of 6.94 is above the 20-day moving average (MA) of 6.07, above the 50-day MA of 5.95, and above the 200-day MA of 5.46, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 61.30 is Neutral, neither overbought nor oversold. The STOCH value of 40.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IPSC	51 Neutral	$78.66M	-2.89	-14.23%	―	4121.12%	83.30%
KPTI	49 Neutral	$118.33M	-0.48	―	―	-3.98%	-29.94%
LTRN	45 Neutral	$36.46M	-1.86	-104.58%	―	―	1.18%
ATNM	41 Neutral	$52.72M	-1.52	-133.09%	―	11.11%	20.65%
BTAI	37 Underperform	$37.83M	-0.18	―	―	-66.96%	71.83%
MDCX	35 Underperform	$37.23M	-0.80	-2237.54%	―	―	-55.95%

Karyopharm Therapeutics Corporate Events

Karyopharm Therapeutics Completes Financing Transactions for Growth

On October 10, 2025, Karyopharm Therapeutics Inc. completed a series of financing transactions, including the issuance of convertible senior notes due in 2028 and 2029, and borrowed $12.5 million under its credit agreement. These transactions are aimed at strengthening the company’s financial position and supporting its strategic initiatives, potentially impacting its market standing and investor relations.

Karyopharm Secures $100M Financing for Clinical Trials

On October 7, 2025, Karyopharm Therapeutics announced a series of strategic financing transactions designed to provide $100 million in financial flexibility and additional capital, extending its cash runway into the second quarter of 2026. These transactions include new term loan borrowings, convertible notes, and a private placement of common stock, aimed at supporting ongoing and planned clinical trials. The company expects to generate approximately $36 million in cash proceeds from these transactions, which are set to close around October 10, 2025. This move is anticipated to strengthen Karyopharm’s balance sheet, equitize near-term debt maturities, and support its Phase 3 myelofibrosis program, potentially redefining treatment standards for the condition.